This is Phase 1, open label, dose escalation study of intravenous PRX004. The purpose of the study is to know how safe and well tolerated PRX004 is in subjects with hereditary ATTR amyloidosis.
This study consist of 2 parts:
Dose escalation phase- in which subjects will be enrolled at each dose level to receive IV PRX004 once every 28 days, up to 3 doses.
Long term extension phase this is an option to continue with monthly infusions for up to 15 additional months.
How understandable was the trial content above?
Hard to understand
Easy to understand